Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
Sign Up to like & getrecommendations! Published in 2019 at "European urology"
DOI: 10.1016/j.eururo.2018.12.042
Abstract: BACKGROUND Several systemic therapeutic options exist for metastatic castrate-sensitive prostate cancer (mCSPC). Circulating tumor DNA (ctDNA) can molecularly profile metastatic castration-resistant prostate cancer and can influence decision-making, but remains untested in mCSPC. OBJECTIVE To determine… read more here.
Keywords: prostate; mcspc; biopsy; dna ... See more keywords
Response to systemic therapy and survival outcomes in de-novo (D1) metastatic castration-sensitive prostate cancer (mCSPC) versus mCSPC with prior local therapy (D0).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.6_suppl.46
Abstract: 46Background: A real-world study (n= 436, PMID: 29707790) suggest that D1 mCSPC has worse outcomes than D0 mCSPC. The objective of our study is to validate these findings in a real-world setting, a... read more here.
Keywords: mcspc; therapy survival; systemic therapy; survival outcomes ... See more keywords
Adverse outcomes (AOs) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with intensified androgen deprivation therapy (ADT+).
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.4_suppl.113
Abstract: 113 Background: mCSPC pts experience adverse outcomes (AOs) with intensified androgen deprivation, resulting in treatment discontinuation; however, there is limited data to identify those at risk. The IRONMAN registry is a global initiative to enroll… read more here.
Keywords: outcomes aos; cancer; intensified androgen; mcspc ... See more keywords
Comparative survival in metastatic castration-sensitive prostate cancer (mCSPC) by prognostic subgroups: A living network meta-analysis.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.4_suppl.171
Abstract: 171 Background: Treatment effects vary by volume of disease and timing of metastatic presentation in patients with mCSPC. Therefore, we updated the existing body of evidence to assess the comparative efficacy of systemic therapy in… read more here.
Keywords: treatment; prognostic subgroups; adt; mcspc ... See more keywords
Understanding variation in treatment intensification for de novo metastatic castration-sensitive prostate cancer (mCSPC): A population-based cohort study.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.4_suppl.69
Abstract: 69 Background: Treatment intensification using androgen receptor signaling inhibitors (ARSIs) or chemotherapy is guideline-recommended for patients with mCSPC based on improved survival and preserved quality of life. However, numerous studies across jurisdictions have shown relatively… read more here.
Keywords: treatment; treatment intensification; variation; mcspc ... See more keywords